Peritoneal and pleural cancers can be treated using PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) and PITAC (Pressurized IntraThoracic Aerosol Chemotherapy).
These locoregional therapies are supported by more than 400 peer-reviewed publications and over 50 clinical trials, including 14 randomized studies.

PIPAC offers key advantages over conventional approaches: it delivers drugs directly to the tumor site, enables local dose intensification with a lower total drug dose, and improves the overall benefit–risk ratio by reducing systemic toxicity. Treatment can be repeated, allowing objective assessment of tumor response through biopsies and enabling patient-specific therapy adaptation. In contrast to HIPEC, PIPAC can deliver a wide range of pharmaceutical and biological substances, including modern targeted and immune-based therapies.